SYN1 and Alzheimer disease: The demonstration that pharmacological interventions can lower synaptic dysfunction markers (like hyperphosphorylated synapsin I) and improve memory behaviors underscores the integral role of modulating neuroinflammatory responses—specifically, the reduction of microglial activation in AD progression.